ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0423

Higher Risk of Preterm Delivery in Women with Rheumatoid Arthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys

Sabrina Hamroun1, Grégoire Martin De Frémont2, Nathalie Costedoat-chalumeau3, Marion couderc4, René-Marc Flipo5, Laure Gossec6, Christophe Richez7, Rakiba Belkhir8, Aline Frazier9, Valerie Devauchelle10, Hubert Marotte11, Jérémie Sellam12, Elisabeth Gervais13, Alban Deroux14, Cedric Lukas15, Emmanuelle Dernis16, Emmanuel Chatelus17, Véronique Le Guern18, Gaëlle Guettrot-Imbert19, Nathalie Lelong20, Camille Le Ray20, Raphaele Seror21 and Anna Molto22, and ENP 2021 and GR2 Study Groups, 1Cochin University Hospital, Paris, Ile-de-France, France, 2Le Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, Guyana, 3University Paris Cité, Paris, France, 4CHU de Clermont-Ferrand, Clermont-Ferrand, 5CHU Lille, Lille, Nord-Pas-de-Calais, France, 6Sorbonne Université, Paris, France, 7Pellegrin Hospital, Rheumatology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Bordeaux, France, 8Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, 9Lariboisière University Hospital, Paris, France, 10UBO, Brest, France, 11Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, 12Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France, 13University hospital, Poitiers, France, 14Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, 15Rheumatology department, CHU Montpellier, Montpellier, France, 16CH LE MANS, LE MANS, Pays de la Loire, France, 17Rheumatology department strasbourg, Strasbourg, France, 18APHP, Hôpital Cochin, Paris, 19Cochin Hospital, Paris, France, 20University of Paris, INSERM Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Paris, France, 21Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 22Groupe Hospitalier Cochin, AP-HP, Paris, France

Meeting: ACR Convergence 2024

Keywords: Cohort Study, pregnancy, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis (RA) regularly affects women of childbearing age1. A higher obstetric morbidity in women with RA is suggested in the literature in several countries, but no comparison between patients with RA and women in the general population is available for France. The aim of the study was to compare adverse fetal, maternal and pregnancy outcomes in women with RA with matched controls from the French general population.

Methods: We conducted a matched comparative study of RA patients included in the GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) national multicentre cohort from 2014 to June 2021 and controls from the French general population included in the French national perinatal surveys (Enquête Nationale Périnatale)2. The latter is a national survey carried out for one week every 5 years and recording around 13 000 births. As births before 22 gestational week (GW) and birth weights < 500 grams were excluded from the French national perinatal survey, the same exclusion criteria were applied to women with RA from the GR2 cohort. Each pregnancy in patients with RA was matched to 4 pregnancies in controls on age group (≤ 29, 30-34, 35-39, or ≥ 40 years), parity, area of residence, and gemellity. These matching variables were chosen according to their association with adverse pregnancy outcomes (potential confounders). Births in the GR2 cohort between 2015 and 2018 were matched to births in the 2016 survey and those between 2019 and 2021 were matched to births in the 2021 survey. RStudio’s MatchIt package was used to match RA patients to controls. The frequency of each adverse pregnancy outcome was compared between the two groups using Fisher’s exact test or Chi-2. Odds ratios (OR) and their 95% confidence intervals (CI) were calculated for each variable.

Results: Of the 92 patients with RA included in the GR2 cohort, 83 (including one twin pregnancy) were retained after excluding births before 22 GW and/or birth weight < 500 grams. They were matched with 332 control pregnancies from the French national perinatal survey (180 pregnancies from the 2016 survey and 152 from the 2021 survey). The mean age of RA patients was 33.7 (+/- 5.06) years and 53% were nulliparous. Preterm birth was significantly higher in newborns of RA patients than in newborns of controls (16.9% versus 6.3%, p < 0.01). Among the cases of preterm birth, only one case of extreme prematurity (at 30 GW) and no case of very extreme prematurity were found in the GR2 cohort. However, there was no significant difference for gestational diabetes nor macrosomia (despite the use of corticosteroids at least once during pregnancy in 42.1% of RA patients), gestational hypertension, low birth weight, severe postpartum hemorrhage, maternal or neonatal transfer to intensive care unit or congenital malformation between the two populations (Table 1).

Conclusion: This study found an increased risk of preterm delivery in RA patients compared with control women in the French general population, which is consistent with an increased risk observed in other countries. These results raise the need for particular attention to obstetrical follow-up in these patients and providing useful insights for physician-patient dialogue.

Supporting image 1

Table 1. Matched comparative analysis of adverse fetal, maternal and pregnancy outcomes in RA patients (GR2 cohort) and control women of the French general population (2016 and 2021 French national perinatal surveys).


Disclosures: S. Hamroun: None; G. Martin De Frémont: None; N. Costedoat-chalumeau: Bristol-Myers Squibb(BMS), 1; M. couderc: None; R. Flipo: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 2, Eli-Lilly, 2, Fresenius kabi, 7, Galapagos, 7, Janssen-Cilag, 2, Lilly, 7, Medac, 7, MSD, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, Roche-Chugaï, 2, Sandoz, 2; L. Gossec: AbbVie, 2, 5, Amgen, 2, Biogen, 5, Bristol-Myers Squibb (BMS), 2, Celltrion, 2, Eli Lilly, 2, 5, Galapagos, 2, Janssen, 2, MSD, 2, Novartis, 2, 5, Pfizer, 2, Sandoz, 2, UCB, 2, 5; C. Richez: None; R. Belkhir: None; A. Frazier: None; V. Devauchelle: AbbVie, 2, BMS, 2, 5, Chugai, 5, Galapagos, 2, Janssen, 2, Lilly, 2, 5, Novartis, 2, Pfizer, 2; H. Marotte: AbbVie/Abbott, 4, 5, 6, Biogen, 5, 6, Bristol-Myers Squibb(BMS), 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 6, Fresenius Kabi, 5, 6, Galapagos, 5, 6, Janssen, 5, 6, Merck/MSD, 5, 6, Nordic Pharma, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Roche, 5, 6, Sanofi, 5, 6; J. Sellam: AbbVie/Abbott, 7, Bristol-Myers Squibb(BMS), 7, Fresenus kabi, 7, Galapagos, 7, Grunenthal, 7, MSD, 7, Nordic Pharma, 7, Novartis, 7, Pfizer, 7; E. Gervais: None; A. Deroux: None; C. Lukas: None; E. Dernis: AbbVie/Abbott, 2, Amgen, 2, Boehringer-Ingelheim, 2, Celgene, 2, Eli Lilly, 2, Galapagos, 2, Gilead, 2, Janssen, 2, Merck/MSD, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, Roche, 2, roche-chugaï, 2, Sandoz, 2, Sanofi, 2, UCB, 2; E. Chatelus: None; V. Le Guern: None; G. Guettrot-Imbert: None; N. Lelong: None; C. Le Ray: None; R. Seror: Amgen, 6, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Pfizer, 6, Roche, 6; A. Molto: AbbVie, 2, 5, MSD, 2, 5, Pfizer, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Hamroun S, Martin De Frémont G, Costedoat-chalumeau N, couderc M, Flipo R, Gossec L, Richez C, Belkhir R, Frazier A, Devauchelle V, Marotte H, Sellam J, Gervais E, Deroux A, Lukas C, Dernis E, Chatelus E, Le Guern V, Guettrot-Imbert G, Lelong N, Le Ray C, Seror R, Molto A. Higher Risk of Preterm Delivery in Women with Rheumatoid Arthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/higher-risk-of-preterm-delivery-in-women-with-rheumatoid-arthritis-a-matched-comparative-analysis-of-the-gr2-prospective-cohort-and-the-french-national-perinatal-surveys/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/higher-risk-of-preterm-delivery-in-women-with-rheumatoid-arthritis-a-matched-comparative-analysis-of-the-gr2-prospective-cohort-and-the-french-national-perinatal-surveys/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology